What Does O-RADS Mean on a Pelvic Report?

O-RADS stands for Ovarian-Adnexal Reporting and Data System. The American College of Radiology built it so that radiologists everywhere describe ovarian and adnexal masses in the same words and attach the same risk estimate to the same appearance. Adnexal means the ovaries, fallopian tubes, and the tissue around them.

The stated goal is blunt: find ovarian cancer while cutting down on surgery that was never needed. Most ovarian masses are not cancer, and the score exists to sort them without an operation.

An O-RADS score is not a diagnosis. It is a probability band attached to what a machine could see on one day.

There are two separate systems, and they are not interchangeable.

O-RADS US is the ultrasound system. Its current version, released in November 2022, is the one most people encounter first, since a pelvic ultrasound is usually the first test.

O-RADS MRI is a different scale used on pelvic MRI, generally after an ultrasound leaves the question open. Same numbers, different criteria, different risk figures.

If your report says only "O-RADS 3," look at which scan it belongs to before comparing it to anything you read.

• O-RADS 0. The scan could not be assessed, often from bowel gas or a mass too large to see fully. A repeat ultrasound is usual, sometimes MRI instead.
• O-RADS 1. A normal ovary. Follicles or a corpus luteum, both part of a normal cycle. Risk of cancer 0%. No follow-up.
• O-RADS 2. Almost certainly benign. Risk under 1%. This holds simple cysts and the classic benign lesions: hemorrhagic cysts, dermoid cysts, endometriomas, paraovarian cysts, and hydrosalpinges.
• O-RADS 3. Low risk. Risk 1% to under 10%.
• O-RADS 4. Intermediate risk. Risk 10% to under 50%.
• O-RADS 5. High risk. Risk 50% or higher.

Size alone can move a lesion. An ovarian lesion that would otherwise be O-RADS 2 becomes O-RADS 3 once it reaches 10 cm.

A simple cyst is anechoic, meaning uniformly black on ultrasound, with a smooth thin wall. Those are the easiest calls.

Complexity is what raises the score. A septation is a wall dividing the cyst into compartments. A papillary projection is solid tissue at least 3 mm tall growing from the cyst wall or a septation, and its presence alone puts a lesion in O-RADS 4.

Blood flow is graded with a color score from 1 to 4, based on color Doppler, which shows moving blood. More flow inside solid tissue pushes the category up.

O-RADS 5 is reserved for the most worrying pictures: an irregular solid lesion, or ascites, meaning fluid in the abdomen, and peritoneal nodules, meaning deposits on the lining of the abdomen.

The 2022 update added a "bilocular" descriptor for a cyst split by one smooth septation, added shadowing as a feature of smooth solid lesions, and changed growth tracking to use the average linear dimension rather than the single largest diameter.

For O-RADS 2, most follow-up depends on size and menopausal status. A simple cyst needs no follow-up at 5 cm or less before menopause, or 3 cm or less after menopause. Above those sizes, a repeat scan is scheduled.

For O-RADS 3, the 2022 update moved away from routine MRI toward short-term ultrasound follow-up, typically at 6 months if the lesion is not removed, then again at 12 and 24 months. MRI is still favored for solid O-RADS 3 lesions. A general gynecologist can manage this category.

For O-RADS 4, the report is asking for gynecologic oncology involvement, either a consultation before any surgery or a full referral.

For O-RADS 5, the recommendation is direct referral to a gynecologic oncologist, with imaging then following that team's protocol.

One rule catches people out. If there are several lesions, or one on each side, management follows the highest score, not an average.

The category is doing something specific: routing you to the right surgeon before the first operation.

Ovarian cancer surgery is not a generic operation. Outcome depends heavily on how completely disease is removed at the first surgery, which is why cytoreductive surgery, also called debulking, is done by gynecologic oncologists. An O-RADS 4 or 5 read is the imaging system saying this should not be a routine cyst removal.

The O-RADS MRI score uses the same 1 to 5 ladder with different published risk figures: about 0% for a score of 1, under 0.5% for 2, about 5% for 3, about 50% for 4, and about 90% for 5.

MRI adds one thing ultrasound cannot do well. It measures how solid tissue takes up contrast over time, plotted as a time-intensity curve, and compares that to the outer myometrium, the muscle wall of the uterus. Tissue that brightens faster than the myometrium is high risk. Tissue that rises more slowly, then flattens into a plateau, is intermediate risk.

CA-125, a blood protein used in ovarian cancer, is not built into O-RADS risk stratification. It is used case by case. There is a reason: CA-125 rises in benign conditions including endometriosis, and screening with pelvic exams, ultrasound, and CA-125 together has shown low predictive value.

More fundamentally, imaging cannot confirm ovarian cancer. Diagnosis requires tissue. The 2026 projection carried on NCI pages — 21,010 new ovarian cancer cases and 12,450 deaths in the United States — is the American Cancer Society's, not NCI's own count, and every one of those diagnoses rested on pathology, not on a score.

• Which system produced this, ultrasound or MRI, and which version
• Which specific features drove the category, such as a papillary projection or color score
• What is the size in centimeters, and am I pre- or postmenopausal by this report's reckoning
• If several lesions were seen, which one set the category
• Is the recommendation follow-up imaging, MRI, or a gynecologic oncology referral
• What date is the next scan booked for

https://pubs.rsna.org/doi/10.1148/radiol.230685 https://pubs.rsna.org/doi/10.1148/radiol.2019191150 https://pubs.rsna.org/doi/10.1148/radiol.204371 https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/O-RADS https://www.radiologyinfo.org/en/info/article-pelvic-imaging-report https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq https://www.cancer.org/research/cancer-facts-statistics.html